InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.84
(
0.06%
)
Bitcoin
65,177.96
(
0.05%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: biomaven0 post# 143112

Sunday, 06/03/2012 9:14:17 PM

Sunday, June 03, 2012 9:14:17 PM

Post# of 252254
Their lead program isn't bi-specific or multi-specific antibody. Their mAb against ErbB3 is probably the most advanced antibody for this particular target. So, it is more the platform for bi-specific/multi-specific I am interested in at the moment. I was interested in MITI's bi-specific many years ago when very few were, MEDX's immunotherapy when very few were. So MACK is the one similar to those two I am out there at the moment. MACK is well below IPO price now.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up